Company intelligence / Profile preview

Lantu Biopharma

Guangzhou City, Guangdong Sheng, Chinaorpha.net ↗

Ownership: Private
Development stage: Other

Overview

Lantu Biopharma is an innovative gene therapy company focused on developing AAV-based treatments for rare and severe genetic diseases. Its lead programs target nervous system and congenital disorders, with two candidates in Phase 2 clinical trials and one in preclinical development. The company has received FDA orphan drug designation for its Menkes disease program and is actively enrolling patients in a Phase I/II trial for spinal muscular atrophy[1][3][7][9].

Therapeutic areas: HematologyRare DiseasesNeurology
Modalities: AAV-based gene therapy (adeno-associated virus vectors)
Industry: Biotech

Drug pipeline

1 asset

vebeglogene autotemcel

Partnerships

VectorBuilder Inc. (CRO/CDMO partnership for vector design, optimization, manufacturing)[5]

Beyond the preview

Go deeper on Lantu Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lantu Biopharma.

Explore the full profile